Open AccessPharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
Author(s) -
Elizabeth Fox,
Brigitte C. Widemann,
Devang Pastakia,
Clara C. Chen,
Sherry X. Yang,
Diane E. Cole,
Frank M. Balis
Publication year - 2015
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-015-2845-1
Subject(s) - vinorelbine , docetaxel , pharmacology , medicine , pharmacodynamics , pharmacokinetics , doxorubicin , chemotherapy , cisplatin
P-glycoprotein (Pgp), an ATP-dependent transport protein, confers multidrug resistance in cancer cells. Tariquidar binds and inhibits Pgp. To assess the toxicity, pharmacokinetics (PK), and pharmacodynamics of tariquidar, we conducted a phase I trial of tariquidar in combination with doxorubicin, docetaxel, or vinorelbine in children and adolescents with recurrent or refractory solid tumors.